Ethanone, 1-(4-chloro-3-fluorophenyl)-2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]- → (S)-N-(1-(3,4-dichlorophenyl)-2-hydroxyethyl)-2-(isopropylamino)-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxamide

HRID 2279458ノート

反応式

HRID 2279458 の反応式
FC1C=C([C@H](N[C:26]([N:28]2[CH2:37][CH2:36][C:35]3[CH:34]=[N:33][C:32]([NH:38][CH:39]([CH3:41])[CH3:40])=[N:31][C:30]=3[CH2:29]2)=[O:27])[C@H]2CCCN2C(OC(C)(C)C)=O)C=CC=1C(F)(F)F.[Si]([O:49][CH2:50][C@H:51]([C:53]1[CH:58]=[CH:57][C:56]([Cl:59])=[C:55](F)[CH:54]=1)[NH2:52])(C(C)(C)C)(C)C.[Si](OCC(C1C=CC([Cl:78])=C(F)C=1)=O)(C(C)(C)C)(C)C.O1CCC(NC2N=CC3CCN(C(OC(C)(C)C)=O)CC=3N=2)CC1>>[Cl:78][C:55]1[CH:54]=[C:53]([C@H:51]([NH:52][C:26]([N:28]2[CH2:37][CH2:36][C:35]3[CH:34]=[N:33][C:32]([NH:38][CH:39]([CH3:41])[CH3:40])=[N:31][C:30]=3[CH2:29]2)=[O:27])[CH2:50][OH:49])[CH:58]=[CH:57][C:56]=1[Cl:59]

参加物

5

反応物 4

HCID 68294408Ethanone, 1-(4-chloro-3-fluorophenyl)-2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-HCID 68295332tert-butyl 2-(tetrahydro-2H-pyran-4-ylamino)-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylateHCID 86705474(S)-2-(tert-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethanamine2 回HCID 131733484(R)-tert-butyl 2-((S)-(3-fluoro-4-(trifluoromethyl)phenyl)(2-(isopropylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-7-carboxamido)methyl)pyrrolidine-1-carboxylate

生成物 1

HCID 60198327(S)-N-(1-(3,4-dichlorophenyl)-2-hydroxyethyl)-2-(isopropylamino)-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxamide

実験手順

To a solution of 1-(3,4-dichlorophenyl)-2-hydroxyethanone (11.86 g, 57.843 mmol, CASRN 113337-38-5), imidazole (5.91 g, 86.764 mmol), and DMAP (0.71 g, 5.7843 mmol) in DMF (100 mL) cooled to 0° C. was added slowly tert-butylchlorodimethylsilane (10.898 g, 72.304 mmol) and the reaction was stirred at RT for 18 h. Water was added and the mixture was extracted with ether. The organic layer was dried, filtered, and concentrated. The crude residue was purified by passage through a SiO2 plug eluting with an EtOAc/hexane gradient (10 to 50% EtOAc) to afford 12.15 g (82.0%) of 2-(tert-butyldimethylsilyloxy)-1-(3,4-dichlorophenyl)ethanone (84). Conversion of 84 to (S)-2-(tert-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethanamine (85) was carried out in accord with the procedure in steps 3 to 5 of example 10 except in step 3,2-(tert-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethanone (62) was replaced with 84. The title compound was prepared from 85 in accord with the procedure in steps 6 and 7 of example 10 except in step 6, 72 was used in place of 26 and 85 was used in place of 68 to afford 136 mg (56%) of I-16: 1H NMR (400 MHz, CDCl3) δ 8.07 (s, 1H), 7.42 (m, 2H), 7.18 (d, 1H), 5.32 (m, 1H), 4.95 (m, 1H), 4.81 (d, 1H), 4.38 (s, 2H), 4.10 (m, 1H), 3.92 (m, 1H), 3.83 (m, 1H), 3.75-3.60 (m, 2H), 2.67 (t, 2H), 2.55 (bs, 1H), 1.22 (d, 6H); LCMS (ACPI-pos) m/z 426.4 (M+H)+.

後処理

  1. customto afford 136 mg (56%) of I-16

出典と根拠

ORDレコード
ord-fe0a2b49dd8041faae936cdc07c28e1c
出典データセット
uspto-grants-2015_09
特許番号
US09133187B2

反応ノート

読み込み中…